Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Leniolisib

f5dc6339-bfef-5162-b815-b75e3397b728 · FDA Approved · targets PI3K

Leniolisib

MeasuredReference

Leniolisib has no high-confidence primary targets in the catalog. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

No high-confidence primary targets.

Top hallmarks

  • tumor promoting inflammation791
  • proliferation737
  • evading apoptosis722

Top pathways disrupted

  • pi3k akt mtor signaling1.5k
  • apoptosis1.3k
  • e2f targets1.2k

Resistance landscape — Leniolisib

MeasuredReference

No variant annotations found on Leniolisib's top targets.

No variant annotations on Leniolisib's top targets.
Open in new tab